LAS VEGAS, Oct. 30 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells, a biological insurance policy for families nationwide and internationally, today outlined its future business strategies in an interview with Dr. Geoffrey John O'Neill, its new Laboratory Director in Las Vegas, by analyst Francis Gaskins.
The entire interview is available at http://www.stoxrox.com/cbai-o'neill.mp3
"We are working to make Cord Blood America a cell therapy service provider, which we believe is where the future resides," Dr. O'Neill explained. "We will become like a cellular pharmacy."
Dr. O'Neill, with a significant business background with companies in the stem cell sector, and author of more than 75 publications in the field, said "stem cells will increase our quality of life. They will be used in medical procedures for nerve regeneration, cartilage regeneration, and the regeneration of muscle and other tissues." He stressed that the new Las Vegas laboratory substantially increases the revenue potential for Cord Blood America.
Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.
Forward-Looking Statements
Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as ''anticipate,'' ''believe,'' ''expect,'' ''future,'' ''intend,'' ''plan,'' and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
Cord Blood America, Inc.
CONTACT: Paul Knopick, E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.
Web Site: http://www.cordblood-america.com/
http://www.corcell.com/
